Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has reaffirmed its Strong Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased its price target from $85.00 to $100.00. Blueprint Medicines' shares are currently trading at $85.93, and the new price target suggests a potential upside of 16.37%. Blueprint Medicines is a biopharmaceutical company focused on developing drugs for diseases caused by abnormal kinase activation.
December 22, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James maintains a Strong Buy rating on Blueprint Medicines and raises the price target to $100, indicating a potential 16.37% increase from the current price.
The reaffirmation of a Strong Buy rating and an increased price target by a reputable analyst firm like Raymond James can lead to positive investor sentiment and potential stock price increase in the short term. The specific mention of Blueprint Medicines and the significant potential upside based on the new price target are likely to draw investor attention and could drive the stock price up.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100